| Literature DB >> 28108511 |
Susanne Kossatz1, Brandon Carney1,2, Melanie Schweitzer3, Giuseppe Carlucci1, Vesselin Z Miloushev1,4, Uday B Maachani3, Prajwal Rajappa3, Kayvan R Keshari1,4,5, David Pisapia6, Wolfgang A Weber1,4, Mark M Souweidane3,7, Thomas Reiner8,4.
Abstract
Diffuse intrinsic pontine glioma (DIPG) is a childhood brainstem tumor with a universally poor prognosis. Here, we characterize a positron emission tomography (PET) probe for imaging DIPG in vivo In human histological tissues, the probes target, PARP1, was highly expressed in DIPG compared to normal brain. PET imaging allowed for the sensitive detection of DIPG in a genetically engineered mouse model, and probe uptake correlated to histologically determined tumor infiltration. Imaging with the sister fluorescence agent revealed that uptake was confined to proliferating, PARP1-expressing cells. Comparison with other imaging technologies revealed remarkable accuracy of our biomarker approach. We subsequently demonstrated that serial imaging of DIPG in mouse models enables monitoring of tumor growth, as shown in modeling of tumor progression. Overall, this validated method for quantifying DIPG burden would serve useful in monitoring treatment response in early phase clinical trials. Cancer Res; 77(8); 2112-23. ©2017 AACR. ©2017 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28108511 PMCID: PMC5392368 DOI: 10.1158/0008-5472.CAN-16-2850
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701